Quetiapine

Generic Name: Quetiapine

Brand Names: Seroquel

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₅N_₃O_₂S

CAS Number: 111974-69-7

Unique Ingredient Identifier: BGL0JSY5SI

Background: Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as Clozapine and Olanzapine.

Indication: Quetiapine is used in the symptomatic treatment of schizophrenia. In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in combination with antidepressant drugs for the treatment of major depression.

Some off-label uses for this drug include the management of post-traumatic stress disorder (PTSD), generalized anxiety disorder, and psychosis associated with Parkinson's disease.

Associated Conditions: Bipolar 1 Disorder, Depressive Episodes, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode

Clinical Trials

Quetiapine Versus Trazadone in Women With Postpartum Depression

Early Phase 1

Not yet recruiting

Conditions: Postpartum Depression

Interventions: Drug: Quetiapine
Drug: Trazodone

First Posted Date: 2024-08-09

Last Posted Date: 2024-08-09

Lead Sponsor: Lawson Health Research Institute

Target Recruit Count: 50

Registration Number: NCT06546358

Locations: 🇨🇦
Parkwood Institute, London, Ontario, Canada

Sequential Multiple Assignment Randomized Trial for Bipolar Depression

Phase 4

Recruiting

Conditions: Depression
Bipolar I Disorder

Interventions: Drug: Aripiprazole/Escitalopram combination
Drug: Lurasidone
Drug: Quetiapine
Drug: Cariprazine

First Posted Date: 2024-05-30

Last Posted Date: 2025-05-15

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 2726

Registration Number: NCT06433635

Locations: 🇺🇸
University of Alabama Birmingham, Birmingham, Alabama, United States
🇺🇸
Steve Strakowski, Bloomington, Indiana, United States
🇺🇸
John Hopkins, Baltimore, Maryland, United States

and more 14 locations

Quetiapine to Reduce Post Concussive Syndrome After Mild Traumatic Brain Injury (mTBI)

Phase 3

Recruiting

Conditions: Mild Traumatic Brain Injury

Interventions: Drug: Quetiapine Fumarate
Drug: TAU

First Posted Date: 2024-03-27

Last Posted Date: 2024-07-23

Lead Sponsor: Foundation for Advancing Veterans' Health Research

Target Recruit Count: 146

Registration Number: NCT06333990

Locations: 🇺🇸
New Mexico VA Healthcare System, Albuquerque, New Mexico, United States
🇺🇸
South Texas Veterans Healthcare System, San Antonio, Texas, United States

Synergistic Effect of Vitamin E & D in Reducing Risk of Effects Associated With Atypical Anti-psychotics

Not Applicable

Completed

Conditions: Antipsychotics and Neuroleptics Toxicity

Interventions: Drug: Risperidone
Drug: Olanzapine
Drug: Quetiapine
Drug: Risperidone and Vitamin D and Vitamin E
Drug: Olanzapine and Vitamin D and Vitamin E
Drug: Quetiapine and Vitamin D and Vitamin E

First Posted Date: 2024-01-11

Last Posted Date: 2024-01-11

Lead Sponsor: Dr Rabia Arshad

Target Recruit Count: 140

Registration Number: NCT06200584

Locations: 🇵🇰
Jinnah Post Graduate Medical Centre, Karachi, Sindh, Pakistan

Efficacy of Melatonin, Low-dose Quetiapine, or Placebo in Patients With Psychiatric Disorders and Comorbid Insomnia

Phase 2

Recruiting

Conditions: Psychiatric Disorders
Insomnia

Interventions: Drug: Placebo
Drug: Melatonin
Drug: Quetiapine

First Posted Date: 2023-10-02

Last Posted Date: 2025-04-24

Lead Sponsor: Lone Baandrup

Target Recruit Count: 255

Registration Number: NCT06062953

Locations: 🇩🇰
Mental Health Center Copenhagen, Copenhagen NV, Denmark

The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

Phase 3

Recruiting

Conditions: Bipolar Depression

Interventions: Drug: Escitalopram
Drug: Sertraline
Drug: Venlafaxine
Drug: Lithium
Drug: Valproate acid
Drug: Quetiapine
Drug: Bupropion

First Posted Date: 2023-08-03

Last Posted Date: 2025-05-16

Lead Sponsor: Dr. Inge Winter

Target Recruit Count: 418

Registration Number: NCT05973786

Locations: 🇦🇹
Medical University Innsbruck, Innsbruck, Austria
🇩🇪
Universitätsklinik für Psychiatrie und Psychotherapie Bielefeld, Bielefeld, Germany
🇩🇪
Klinik für Psychiatrie und Psychotherapie der Universitätsmedizin Mainz, Mainz, Germany

and more 10 locations